ArticleCureus2026
Residual Primary Breast Cancer After Chemotherapy: Assessment of Recurrence and Survival.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The presence of residual breast cancer after neoadjuvant chemotherapy can influence the rate of distant recurrence. Objective To identify clinical and tumoral risk factors predicting recurrence, and to evaluate their impact on distant recurrence-free survival (DRFS), in patients with stage III breast cancer who did not achieve a pathological complete response (non-pCR) after neoadjuvant chemotherapy Material and methods This retrospective study evaluated the association between risk factors and recurrence in patients who did not achieve a pathological complete response using relative risk. Five-year distant recurrence-free survival was calculated for three risk groups: low-risk, intermediate-risk, and high-risk. The discriminative ability for predicting recurrence was assessed using receiver operating characteristic methodology. Two Cox regression analyses were performed to identify independent predictors of relapse. Results Residual tumor was present in 69.8% (88/126) of patients, with 47 total recurrences. Significant risk factors included clinical stage IIIB, grade 3 tumors, and luminal B and HER2+ subtypes, with relative risks (RRs) of 3.5 (95% CI: 1.6-7.5), 3.7 (95% CI: 1.7-8), 3.4 (95% CI: 1.3-8.6), and 4.2 (95% CI: 1.1-15), respectively. Recurrence rates for the low-risk, intermediate-risk, and high-risk groups were 22% (10/45), 36% (19/53), and 64% (18/28), respectively, with corresponding five-year distant recurrence-free survival rates of 67% (95% CI: 43-83%), 61% (95% CI: 46-73%), and 36% (95% CI: 18-54%). The positive likelihood ratios were 0.38 for the low-risk group, 0.71 for the intermediate-risk group, and 2.94 for the high-risk group. Cox regression analysis showed that the intermediate-risk and high-risk groups had an increased risk for recurrence of 3.3 (95% CI: 1.2-9) and 5.4 (95% CI: 1.9-15) times, respectively, compared to the low-risk group. Conclusions This staging that includes a clinical and tumoral characteristics scale facilitates the early optimization of subsequent systemic treatments, allowing for therapeutic adjustments prior to the development of clinical metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.